Aerpio Therapeutics Announces Presentation of Positive Results of AKB-9778 in Patients with Diabetic Retinopathy from TIME-2 Phase 2a Study
CINCINNATI--(BUSINESS WIRE)--Aerpio Therapeutics, Inc., a biopharmaceutical company focused on advancing first-in-class treatments for the eye, today announced promising results in diabetic retinopathy from the company’s phase 2a study (“TIME-2”) of its lead candidate, AKB-9778, a first-in-class Tie2 activator. AKB-9778, dosed at 15 mg BID subcutaneously, alone and in combination with Lucentis® (ranibizumab injection dosed at 0.3 mg intravitreally), improved underlying retinopathy according to
